Imunon Sets Enrollment and Interim Analysis Timelines for OVATION-3 Clinical Trial
Imunon, Inc. (IMNN) provided updates regarding its clinical development progress during its Q3 2026 earnings call. The company is focusing on the advancement of three key programs, specifically highlighting continued enrollment for the OVATION-3 study. Management has established specific long-term milestones, aiming to reach 50% enrollment in the OVATION-3 trial by the first quarter of 2028. Following this progress, the company anticipates conducting an interim analysis of the data in the first quarter of 2030.
Tickers: $IMNN